Director of the Clinical Research Center (KFC),Karolinska Institute,Sweden
Professor Moustapha Hassan is currently director of Preclinical Laboratory, the preclinical research facility at Karolinska University Hospital, Huddinge, Sweden, as well as Professor of Transplantation Research at Karolinska Institutet Huddinge, Stockholm, Sweden. He is a consultant to several hospitals in Sweden and many hospitals in Europe for personalized treatment prior to stem cell transplantation and treatment for hematological malignancies. His particular focus has been on increasing treatment efficacy and reducing side effects for transplanted children, and on optimizing treatment with busulfan/cyclophosphamide in stem cell transplantation. Professor Hassan developed a liposomal formulation enabling intravenous administration which is currently undergoing clinical trials. Professor Hassan’s current research projects focus on personalizing treatment through genome analysis, nanomedicine and improvement in pre-transplant medicine.
Physician executive with 19 years of experience across geographies, medical functions and therapeutic areas; partnering effectively with internal and external stakeholders to enable original research, life-cycle management, new product launches, medical affairs, alliance management, in-license and regulatory submissions.
Author of over 40 publications, regulatory documents and clinical trial dossiers; NDA and IND submissions including face-to-face presentations at FDA, EMA and C-FDA (China).
Portfolio management and leadership experience in drug safety , drug development and medical affairs.
Track record of leading cross-functional teams, talent management, objectives setting and performance evaluation ensuring a culture of accountability, quality, ethics, compliance and scientific excellence.
Shaun Lonergan is Vice President and General Manager of Precision Medicine at Metabolon, Inc. His past experience includes commercialization of several major research and diagnostic instrument platforms. Mr. Lonergan participated in or led successful sale or public offering of several companies while holding senior management positions at Boehringer Mannheim (Roche), Perceptive Biosystems (Thermo), Third Wave Technologies (Hologic), NimbleGen (Roche), 454 Life Sciences (Roche), Ibis Biosciences (Abbott Molecular) and Seegene, Inc. He served as CEO of Nerites Corporation (DSM), attaining more than $7 million in grant awards. Earlier, he was the clinical director at Oncology Laboratory, Inc. leading the in-vitro chemosensitivity assay clinical team. Mr. Lonergan earned his Master of Science degree in microbiology from the University of Rhode Island
Dr. Reiter is the Bing Professor of Urologic Oncology and Director of UCLA’s prostate cancer program. He attended Stanford Medical School, completed his urologic training at Stanford and Baylor College of Medicine, and completed additional fellowship training in urological cancer at the National Cancer Institute. Dr. Reiter was awarded the Outstanding Achievement Award by the Urologic Oncology branch of the National Cancer Institute.
His clinical and research interests include improving management of prostate cancer using functional MRI and molecular imaging of the disease, robotic prostatectomy, molecular biology of prostate cancer progression, and precision medicine and clinical trials for management of high-risk and metastatic prostate cancer. He specializes in robotically-assisted prostatectomy and cystectomy, as well as open surgery, with robotic experience dating back to 2004, for bladder, prostate, and renal malignancies. Dr. Reiter is involved in all aspects of urologic oncology, with an emphasis on prostate cancer, and brings extensive experience in robotic surgery and the applications of translational research and the latest in MRI and molecular imaging to the management of men with this disease.
He is Principal Investigator on UCLA’s Prostate Cancer SPORE, a 12 million dollar federal grant that is focused on translational research in prostate cancer.
VP Regional Medical Affairs EEMEA (Eastern Europe, Middle East & Africa)
Wolfgang Golisch MD PhD, VP Regional Medical Affairs EEMEA (Eastern Europe, Middle East & Africa) at F. Hoffmann La Roche, Switzerland. Board certified Anesthesiologist, University of Göttingen Medical School and Hospital, Germany. Joined the pharmaceutic industry in 1998 as a clinical research physician at Boehringer Ingelheim, Germany. Extensive experience in pharmaceutical medicine incl. clinical research in different therapeutic areas (respiratory, cardiovascular, immunology, neurology and oncology).
Established clinical trial activities across different markets including Western Europe, Latin America and EEMEA.
Oversees at F. Hoffmann La Roche all medical activities in region EEMEA including medical scientific product support, regulatory affairs, pharmacovigilance and clinical operations.
Professor Reza Razavi is Vice President & Vice-Principal (Research & Innovation) King’s College London and Director of Research at King’s Health Partners. He is also the Leader of the Imaging and Biomedical Engineering Clinical Academic Group, Professor of Paediatric Cardiovascular Science at King’s College London and Consultant Cardiologist at Guy’s and St Thomas’.
Professor Razavi qualified in Medicine at St. Bartholomew’s Medical School in 1988. He later trained in Paediatrics and Paediatric Cardiology and started a research career following his clinical training. His research is in imaging and biomedical engineering related to cardiovascular disease. One key area of focus is cardiac MRI in relation to congenital heart disease, electrophysiology and heart failure, image guided intervention, XMR (X-ray and MRI) guided cardiac catheterisation and methodological advances to move to faster 3-Dimensional cardiac imaging.
Vice President, Drug Substance Team, Samsung Bioepis Co., Ltd
Brian Hosung Min Vice President, Drug Substance Team, Samsung Bioepis Co., Ltd Dr. Brian Hosung Min is currently the Vice President of Drug Substance Team at Samsung Bioepis. He is in charge of drug substance development, scale-up and validation of all Samsung Bioepis’ products in its pipeline. Before moving to this position, he served as Vice President of Strategic Business development at Samsung Electronics. In this role, he was one of the key members in setting up the biopharmaceutical business at Samsung. Prior to joining Samsung in 2008, Dr. Min was a Scientist at Amgen for over 10 years in charge of protein therapeutic generation and optimization, developing multiple protein and antibody therapeutics successfully. He holds a B.A. from University of California, Berkeley and a Ph.D. from University of California, Los Angeles.
Cluster Director (Site Managament & Monitoring) Middle East Africa (MEA) at AstraZeneca
Cluster Director (Site Managament & Monitoring) Middle East Africa (MEA) at AstraZeneca
The Site Management & Monitoring Cluster Director (CD) is accountable for clinical study strategy planning and execution, delivery the committed part of all interventional studies under his/her supervision per agreed resources, budget and timelines complying with AZ Procedural Documents, international guidelines such as ICH and GCP as well as relevant regulations.
SM&M Cluster Director MEA reports to the Regional Director Site Management & Monitoring EMEA and is a member of the EMEA Regional Leadership Team.
Chief Executive Officer of Ministry of National Guard – Health
President , King Saud bin Abdulaziz University for Health Sciences
Dr. Bandar Al Knawy holds the position of Chief Executive Officer (CEO) at Health Affairs, Ministry of National Guard, an organization which comprises five medical cities in the five major regions of Saudi Arabia as well as holding the position of President, King Saud bin Abdulaziz University for Health Sciences, since February 2009. He also served as the General Supervisor for the Royal Clinics of the late King Abdullah Bin Abdulaziz Al Saud, Custodian of the Two Holy Mosques from 2009 until January, 2015.
He obtained his MBBS from King Abdulaziz University, Jeddah, Faculty of Medicine in June 1985. He completed his residency training in Internal Medicine in 1990 and obtained his Gastroenterology Fellowship in 1992 from Dalhousie University, Halifax, Nova Scotia, Canada. He holds a fellowship in Internal Medicine from the American and Canadian Boards, as well as the American Board Certification in Gastroenterology.
He is a strong advocate of Quality and Patient Safety and pioneered the development of the Medication Safety Program in Saudi Arabia in addition to many Patient Safety initiatives at NGHA, and was responsible in the recent commissioning of major healthcare expansions at NGHA, including, King Abdullah International Medical Research Center, King Abdullah Specialized Children Hospital and King Abdullah bin Abdulaziz International Foundation for Humanitarian Activities, and the inception of the system-wide EMR. He currently represents MNGHA at the National Health Services Council.
He has had numerous scientific and medical articles published in international journals. He is the guest editor of the February 2010 issue of Clinics in Liver Disease – Healthcare Associated Transmission of Hepatitis B & C Viruses. Dr Al Knawy is the author of a book entitled “Hepatology: A Practical Approach”, published in December 2004, and a textbook entitled Hepatocellular Carcinoma: A Practical Approach”, released in September 2009.
He is a highly skilled and qualified medical professional who is committed to provide, with all sincerity and dedication, the highest quality patient care for the betterment and the development, of National Guard Health Affairs.
Chief Executive Officer Of King Faisal Specialist Hospital & Research Centre (Gen. Org.)
Member & Secretary General of the Board of King Faisal Specialist Hospital & Research Centre (Gen. Org.)
After graduating with a Bachelor’s Degree in Medicine and Surgery from the King Saud University, Saudi Arabia Dr Al Fayyadh completed his Residency in Pediatrics at Tufts University followed by a fellowship in Pediatric Cardiology at Columbia University, New York and in 1996 he received specialty certification from the American Board of Pediatrics. In 2000, Dr Al Fayyadh achieved the American Sub-Board of Pediatric Cardiology. At the conclusion of his training, he completed subspeciality fellowship in Pediatric Cardiac Electrophysiology at Baylor College of Medicine, Houston.
An advocate for continuing education, Dr Al Fayyadh maintains his currency by attending professional development courses. In 2015, he successfully achieved his Master Degree in Medical Management from the University of Southern California, USA.
Early in his career and in parallel with his clinical practice and academic contributions, Dr Al Fayyadh developed a passion for research and continues to be an active researcher. His work has been awarded multiple grants including the Dubai Harvard Foundation for Medical Research Grant for an international multi-center project for the Discovery of Genetic Causes for Human Congenital Malformations. The King Abdulaziz City for Science and Technology also awarded a number of grants to Dr Al Fayyadh as Principal Investigator for the following two projects: Genetics of Mendelian Cardiovascular Disorders in Saudi Arabia, and Electrocardiogram Screening for School Children: A Cross-Sectional, Population-Based Study.
Dr Al Fayyadh has continued his research and academic activities throughout his professional career and has published articles and abstracts in multiple peer-reviewed medical journals, both national and international. In addition, he has served in editorial, editorial board member and reviewer roles including being Editor of two international journals and is a member of a variety of professional societies. He is a talented presenter and has participated as an invited speaker at numerous national, regional and international symposia.
Throughout his career, Dr Al Fayyadh has held increasingly senior positions where his clinical and administrative expertise and experience have contributed to improving the level of healthcare delivery. He is a member of various government committees and is committed to the success of Saudi Arabia’s National Transformation Program which is a component of the government’s Vision 2030.
In October 2017, Dr Al Fayyadh was appointed as Chief Executive Officer of King Faisal Specialist Hospital and Research Centre (KFSH&RC) in Riyadh, Saudi Arabia, a leading tertiary healthcare facility in the region. In this role he is responsible for all facets of the General Organization ranging from clinical to nursing, research, academia to administration. This follows his previous appointment as Deputy Executive Director, Medical & Clinical Affairs at KFSH&RC, Riyadh, where he was responsible for a large portfolio of medical departments’ operations, pharmacy, patient services, and system applications. His focus centered on patient experience, staff development and the work environment, productivity and improving operational efficiency. Dr. Al Fayyadh also served as Deputy Director, Heart Centre and Project Executive for the Cardiology Information System at KFSH&RC and recently he worked as an advisor to the Director of the Vision Realization Office at the Ministry of Health.
Vice-President for Research Support, King Abdulaziz City for Science and Technology
Professor Dr. Abdulaziz Bin Mohammed Al-Swailem has obtained PhD from Sheffield University, United Kingdom, in Biotechnology and Genetic Engineering. He currently holds the post of Vice President of King Abdulaziz City of Sciences and Technology for Scientific Support. He has previously served as Director for the Natural Resources and Environment Research Institute and Chairman of the Biotechnology Research Centre in KACST. He was appointed as Vice President of King Abdulaziz City of Sciences and Technology for Scientific Support in October 2010 and was also appointed as Research Professor in the same year.
Dr. Al-Swailem worked on numerous research projects in the field of Genomics, Proteomics, Biosafety and genetic modification. He has a number of scientific reports and articles in Biotechnology, Genetic Engineering and Bioethics.
Dr. Al-Swailem served as President and member of various local and international councils and boards. He served as Chairman of the International Governmental Bioethics Committee – UNESCO between 2009 and 2011 and Chairman of the National Committee of Bioethics, NCBE. He was selected as advisor for UNISCO and WIPO and Chairman of the supervisory committee for Traffic Safety Strategic Plan. He is a Member of the Board of Directors of the Communications and Information Technology Commission, Member of the Preparatory Committee of the Supreme Council for Petroleum and Mineral Resources, Member of the Supreme Council of Al Marai Prize for Scientific Innovation and the Prize’s General Secretary and Member of the Board of Environment.
Executive Director of the King Faisal Specialist Hospital and Research Centre and Chief Executive Director of the King Salman Center for Disability Research
Sultan Al-Sedairy is a Saudi scientist born in 1955 in Riyadh, Saudi Arabia. He currently holds the following positions: Research Centre executive director (King Faisal Specialist Hospital and Research Centre, since 1996), chief executive director (King Salman Center for Disability Research, since 2004), and professor, College of Medicine (Alfaisal University, since 2011).
Al-Sedairy received his Bachelor of Science degree in Biology/Chemistry in 1979 from the University of Puget Sound (Tacoma, Washington). He received his diploma in Medical Technology in 1981 from the Cleveland Clinic Education Foundation (Cleveland, Ohio). He completed his MA in Pathology in 1982, his MPhil in 1984, and his PhD in 1987 (Pathobiology, with focus on tumor immunology), Thesis: Human Tumor Antigens Identified with Monoclonal Antibodies  all from Columbia University (New York). His post-doctoral fellowship was completed under the supervision of Prof. H. Vogel in 1987 (March – October) at the Department of Pathology, College of Physicians and Surgeons (Columbia University).
Member, Biotechnology Committee of the King Abdulaziz City for Science and Technology Member, Kingdom’s Experts’ Council in the field of Medical Science and Technology Member, Oversight Committee for the National Strategy for Science and Technology and Innovation Member, Technology Advisory Council, Saudi Technology Development and Investment Company (TAQNIA)
Vice President, International Network for Cancer Treatment and Research Member, Governing Council, International Network for Cancer Treatment and Research Member of the Tumour Biology Committee, International Union Against Cancer Member of the Board of Trustees, Dubai Harvard Foundation Member of the Scientific Advisory Committee, Dubai Harvard Foundation Member of the Scientific Committee, InNaBioSanté Foundation Member of the Executive Committee, International Cancer Genome Consortium Member of the International Scientific Steering Committee, International Cancer Genome Consortium Member of the Executive Committee, International Rare Diseases Research Consortium Member of the Advisory Board, KACST-UCSD Joint Center for Excellence in Nanomedicine & Engineering, University of California, San Diego, USA Fellow, Royal Society of Medicine Member of the Board of Directors, Taqnia International
Hisham Aljadhey, PharmD (Purdue), MS, PhD (UNC) Dean, College of Pharmacy Supervisor of Pharmacy Services at King Saud University Medical City Director of Medication Safety Research Chair King Saud University
Hisham Aljadhey, PharmD (Purdue), MS, PhD (UNC)
Dean, College of Pharmacy
Supervisor of Pharmacy Services at King Saud University Medical City
Director of Medication Safety Research Chair
King Saud University
Dr. Aljadhey is the Dean of Pharmacy College and Supervisor of Pharmacy Services at King Saud University Medical City, King Saud University where he serves as director of Medication Safety Research Chair. He was the Vice Dean for Graduate Studies and Research and Vice Dean for Academic Affairs at the same college. He had adjunct appointment in the University of North Carolina, University of Aberdeen, and University Science of Malaysia. He received his baccalaureate degree from King Saud University and his doctor of pharmacy (PharmD) and master from Purdue University. He completed an ASHP accredited residency at Winchester Medical Center, Virginia. In 2008, Dr. Aljadhey earned his Doctor of Philosophy in pharmacoepidemiology and medication safety from the University of North Carolina at Chapel Hill in the United States of America.
Dr. Aljadhey is a reviewer for several international scientific journals and Associate Editor for both Pharmacoepidemiology and Drug Safety and Journal of Asian Association of Schools of Pharmacy journals. He is the founding chair for the Gulf chapter of the International Society for Pharmacoepidemiology. Dr. Aljadhey supervised more than 25 graduate students and published more than 80 peer reviewed publications. He is a member of the pharmacovigilance advisory committee in the Saudi Food and Drug Authority and member in the committee for the Pharmacovigilance guidelines. He is a member in the Board of Trustees and the Saudi Pharmacy Scientific Board at the Saudi Commission for Health Specialties. Dr. Aljadhey is a member of the International Expert Group on Patient Safety Research in Primary Care at the World Health Organization. Dr. Aljadhey served as consultant to several colleges of pharmacy and universities and currently he is a member in the Board of Directors of the Asian Association of Schools of Pharmacy. He was awarded the Andrew McAfee Award for scientists by the International Society for Pharmacoepidemiology.
Dr. Aljadhey is the Dean of Pharmacy College and Supervisor of Pharmacy Services at King Saud University Medical City, King Saud University where he serves as director of Medication Safety Research Chair.
Governor of the General Authority of Small and Medium Enterprises in Saudi Arabia
Dr. Ghassan Ahmed Abdullah Al-Sulaiman, Ph.D., is the Founder of Gulf One Bank of Bahrain. Dr. Al-Sulaiman is the Founder, President and Chairman of Ghassan Ahmad Al Sulaiman Development Company. He is also the Founder of Abna Abdullah Al Sulaiman Company Limited, Ghassan A. Al-Sulaiman Furniture Co. Ltd, Ghassan Al-Sulaiman & Partners Company, House of Development Co. Ltd., Tauzeef Human Resourcing, Training & Education Services Co. Ltd, Sahary for Computer Services Co. Ltd, Propaganda Advertising Company, Manafith International Marketing Company Ltd., and Techno Media Co. He is the Governor of the General Authority of Small and Medium Enterprises in Saudi Arabia. Dr. Al-Sulaiman serves as the Founder and Chairman of City Center Development Company, KSA, Jazirah Tourism Investment Company and Saudi Venture Capital Investment Co. He serves as the Chairman CV of Ghassan Ahmed Al-Sulaiman Development Company Ltd. He is also on the Board of Directors of the Private University – Makkah Region, the Visually Impaired Service Center and the Saudi Organization for the Handicapped. Dr. Al-Sulaiman is the Chairman of Minaret Business Organization, Saudi-Turkish Business Council, Unizah Investment Company, Ghassan Ahmed Al Sulaiman Trading, Al Mathaaq Development, Altalea Trading Co, Delta United Company Ltd, Goknur Foods Import Export Trading & Production Company and Kayant Co. Dr. Al-Sulaiman serves as Chairman of the Board of several private sector entities, including the Ghassan A. Al-Sulaiman Furniture Co. Ltd. (IKEA). He is a Board Member of Bin Sulaiman Holding Co, Al Maghrabi Hospitals Co and Namaa Company. He also serves on the Boards of Directors of Savola Company, Arabia Cement Company, In addition to this, Dr. Al-Sulaiman serves as the Chairman of Ghassan Ahmad Al Sulaiman Holding Co, Khaleej Salman Bay Development Co, Saudi Chamber of Commerce and Industry of Jeddah, Al Sulaiman Inter-market Co. Ltd and Siraj Capital Ltd. He is the Chairman of the Board of Directors of Jeddah Dawah Center He is the Chairman of Kingdom of Saudi Arabia. He is a Member of the Board of Directors of Holy Quran Memorization Int’l Org, Dar Al-Islam Charity, Abdullah Al-Sulaiman Charity Organization, Businessmen Union of Islamic Chamber of Commerce & Industry and Tourism Development Board of Jeddah. Dr. Al-Sulaiman is a Director of Diyafat Albalad Alameen. Dr. Al-Sulaiman serves as the Vice Chairman of Sawary Trading & Contracting Co. He serves as a Director of Jeddah Province Council, Bin Sulaiman Holding, Maghraby Hospitals & Centers Company Ltd., and Global Gypsum Company Ltd. Previously, he had served on board of many profit and non-profit organizations. He served as a Director of Savola Group Company until July 1, 2013. He served as the Chairman of Venture Capital Bank. Dr. Al-Sulaiman was also the Co-Chairman of National U.S.-Arab Chamber of Commerce. He was the Chairman of the Jeddah Chamber of Commerce and Industry. Dr. Al-Sulaiman served as Non-Executive Independent Director of Arabian Cement Co. until August 4, 2016. He has 31 years of experience. Dr. Al-Sulaiman received a Ph.D. in Business Administration in 2004 from Hull University, an M.B.A. with honors from University of San Francisco in 1980 and a B.Sc. in Business Administration from Menlo College.
Executive Director at the King Abdullah International Medical Research Center (KAIMRC), in Riyadh, Saudi Arabia.
Executive Director at the King Abdullah International Medical Research Center (KAIMRC), in Riyadh, Saudi Arabia.
Dr. Ahmed Alaskar is a Consultant and Associate Professor, Adult Hematology & HSCT, King Abdulaziz Medical City, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs. He is also the President of Saudi Society of Blood and Marrow Transplantation (SSBMT) and the Executive Director, King Abdullah International Medical Research Center. Previously he assumed the position of Head Division of Adult Hematology & Hematopoietic Stem Cell Transplantation and Chairman of Department of Oncology, King Abdulaziz Medical City – Riyadh.
Dr. Ahmed Alaskar gained his MBBS in February 1989 from King Saud University, Riyadh and completed medical residency training at University of British Columbia, Vancouver, Canada in 1995. In August 1995, he obtained his American Board of Internal Medicine and in June 1997 became Fellow of the Royal College of Physicians & Surgeons of Canada. Further, Dr. Alaskar completed his fellowship training in Hematology at the University of British Columbia, Vancouver, Canada where he obtained his Canadian Board in Hematology, American Board in Hematology and completed further Fellowship in Leukemia and Bone Marrow Transplantation in December 1998.
Dr. Alaskar has a number of publications and involved in numerous local and national committees and member of several International Societies.
Advisor,Minisrty of Health, Kingdom of Saudi Arabia
Ibrahim Aljuffali is the Executive Vice President for Drug Sector at Saudi FDA. Dr. Aljuffali earned his PhD degree in Pharmaceutical sciences from the University of Georgia (UGA) with research emphasis in Nontechnology and Pharmacokinetics/Pharmacodynamics. Dr. Aljuffali also earned a Master of Science Degree in Pharmacy with an emphasis in Regulatory Affairs and graduate diploma in Clinical Trials Design & Management from University of Georgia.
Dr. Aljuffali Also serve as an Associate Professor at King Saud University. He chairs and patriate in different local and national committee related to health and drug regulation.
Eng. Nizar Al-Hariri comes with over 23 years’ of successful track record of business development in both government and private sectors. Experienced across all aspects of business developments from concept to JV set-ups, contractual negotiations and funding arrangements to major project management, strategic planning and organization structuring. He has proven ability in developing business strategies and plans based on exceptional analytical skills, achieving business goals and taking full P&L responsibility. Having worked in SIDF for ten years and managed Capital Advisory Group for five, he has a recognized management and consultancy records appointed him to manage the advisory services for the Economic Offset Program, EOP and Public Investment Fund, PIF between 2003 and 2006. Later, Eng. Al-Hariri was assigned as CEO for CAD Middle East for Pharmaceutical Industries. He was responsible for introducing a ground breaking concept of building the first GMP state-of-the-art Active Pharmaceutical Ingredients (API) facility in Saudi Arabia and the MENA region.
Eng. Nizar Al-Hariri has a BSc in Chemical Engineering from King Saud University, and post graduate from the University of Cambridge, Engineering Dept. in Design, Manufacture & Management – ACDMM
Dr. Mazen Hassanain graduated from King Saud University’s College of Medicine in Riyadh, Saudi Arabia, He then joined the academic staff of the Department of General Surgery at KSU. He went on to complete 5 years of training in General Surgery at McGill University. He is a Fellow of the Royal College of Physicians and Surgeons of Canada (FRCSC), a Fellow of the American Board of Surgery (FACS) and a Fellow of the American Society of Transplant Surgery(ASTS). He holds certificates in both Hepato-Pancreato-Biliary Surgery and Transplantation Fellowship and ASTS Kidney Transplant Surgery from McGill University.
He has presented 54 orals/posters at 25 national and international meetings, which resulted in 61 peer-reviewed publications. Dr. Hassanain’s ability to balance a very busy clinical practice with his research activities has allowed him to simultaneously complete a Ph.D. degree in the Division of Experimental Surgery.
His expertise include Hepatopancreatobiliary surgery, Solid Organ Transplant, Liver Regeneration Post resection, Cancer Genetics and Personalized therapy, Fatty Liver Disease Biomarkers.
Dr. Hassanain had been had been the Director General of the General Administration of Research and Studies at the Ministry of Health in Riyadh. He is currently an Associate Professor in the Department of Surgery, a member of the HPB and Solid Organ Transplant team at King Saud University College of Medicine, an Adjunct Professor at the Department of Oncology at McGill University and also at the Hubert Department of Global Health at Emory University. He is now the Director of the KSU Vaccine and Biologics Development Program.
Director , Medical Biotechnology Park Head, Strategy and Business Development, KAIMRC. MNG-HA
Director , Medical Biotechnology Park
Head, Strategy and Business Development, KAIMRC. MNG-HA
Dr. Haoudi is currently leading the R&D Strategy and Business Development at King Abdullah International Medical Research Center at the Ministry of National Guard Health Affairs and is also Visiting Scientist at Boston Children’s Hospital-Harvard Medical School.
Dr. Haoudi held several senior R&D positions in the academia, government and private sectors including Executive Director for R&D, Founding Vice President for Research at Qatar Foundation and Chairman of Exceptional National Priorities Grants Programs. Dr. Haoudi was also Research Professor of cancer and infectious diseases and a fellow of the US National Institutes of Health. He has also held several other positions in elite research and education institutions including Visiting Professor at Harvard Medical School (USA) and a fellow at Institut Pasteur (France) and had served as consultant and advisor to several biotechnology and pharmaceutical companies.
Dr. Haoudi was elected as a member of the Royal Academy for Science and Technology since 2006 and graduated from University Paris XI, France in 1996 with a doctoral degree in cellular and molecular genetics and received executive education from Harvard Business School in Corporate management and strategy. Dr. Haoudi has also founded and served as the Editor-in-Chief for the Journal of Biomedicine and Biotechnology over 8 years.
Dr. Khalid Al-Saleh is an associate professor at the Industrial Engineering Department, College of Engineering, King Saud University. He obtained his PhD from Birmingham University, UK, in 2004. His BSc in industrial engineering was obtained from King Saud University in 1993. His research interests focus on Human Factors Engineering and ergonomics. He is also a member of the Association of University Technology Managers (AUTM). Furthermore, He is a funding-member of the Saudi Inventors Society. In 2007 he served as the director of the Intellectual Property and Technology Licensing program at King Saud University. He is a member of the Higher Committee of Unifying Intellectual Property Rights under One Umbrella. He published several papers in related journals and conferences. Since 2013 to present, he is serving as a CEO of Riyadh Valley Company, the investment vehicle of King Saud University.
Director of Scientific Research Center , Medical Services Department for Armed Forces
Abdulrahman Khazim Al-Asmari is known for his scientific contributions in the field of toxinology. At present he is undertaking research projects to study the natural toxins such as the venoms of scorpion and snakes and their different fractions for treating different diseases including cancer. He is the author and coauthor of more than 50 publications which were published in reputed international and national journals. He is also the author of several books and book chapters published by International publishers of repute. He is a member of the Editorial Board of many journals of prestigious national and international scientific societies and committees.
1996 Ph.D., London, UK in Clinical Biochemistry, (Immuno-toxicology as post-doctoral subspecialty) Queen Mary and Westfield College, Medical College of St Bartholomew’s, City of London. University of London, London, UK.
1994 M.Phil., Proteomic studies of venomous snake venoms and their enzymatic and biological activities, (Biochemistry), M.Phil. Thesis, London, UK.
1992/93 Diploma, Environmental Pollution Research National Institute of Standards and Technology, Maryland, USA.
1991 M.Sc., Toxicology, (Toxicity Studies of Concurrent Use of Alcohol, Caffeine and Nicotine on some Aspects of Reproduction) Pharmacy College, King Saud University, Riyadh, KSA.
1983 B. Pharm, Pharmacy College, King Saud University, Riyadh.
2012 Application training of Micro Array DNA techniques Riyadh, KSA.
2010 Application training in LC/MS (LCQ Fleet Ion Trap Mass Spectrophotometer, Thermo) Thermo Scientific Corporation, Riyadh, KSA.
2007 Development and interpretation of toxico-kinetic data for risk on safety assessments, Montreal, Canada.
2007 Molecular and biochemical mechanism in Teratogenesis involving reactive oxygen species, Montreal, Canada.
2001 Clinical Toxicology Course, Pediatrics and Women’s Hospital, College of Medicine, University of Adelaide, Australia.
2001 The Basics of Molecular Biology, King Faisal Specialist Hospital and Research Center, Riyadh, KSA.
1998 Advanced Course in Medical Statistics Armed Forces Hospital
1994 Radiation Protection Training Course, University of London, London, UK.
1992 Ground-Based Smoke Sampling Techniques Training Course, National Institute of Standards & Technology Gaithersburg, Maryland, USA.
1992 Methods of Scientific Research, Training Course, College of Health Science, State of Bahrain.
1990 Monitoring of Medical Supplies Storage, Institute of Public Administration, Riyadh, KSA.
PRESENT & PREVIOUS POSITIONS
June 2016 Consultant & Director of Scientific Research Center, MSD, for Armed
Till date Forces, Ministry of Defense, Riyadh, KSA.
2010-2016 Consultant & Director of Research Center, PSMMC, MSD,
Ministry of Defense, Riyadh, KSA.
2001-2010 Deputy Director & Consultant Clinical biochemists, Research Center, PSMMC, Ministry of Defense, Riyadh, KSA.
1997-2001 Research Scientist, Research Center, PSMMC, Ministry of Defense, Riyadh, KSA.
1987-1997 Clinical Pharmacist Drug Information and Poisoning Center, PSMMC, Riyadh, KSA.
1983-1985 Clinical Pharmacists at King Abdulaziz Hospital Dhahran, Kingdom of Saudi Arabia.
Badir Program for Technology Incubators
Nawaf Attaf Al Sahhaf has worked in the Badir Program for Technology Incubators of King Abdulaziz City for Science Technology, for the past four years. In 2013, he became the Badir chief Executive Officer and restructured the organisation to strategically position it to become an internationally recognised world class incubation programme and play a major role in improving the effectiveness of the Saudi entrepreneurial and innovation eco-systems. In 2012 as Badir’s commercialisation and funding director, he led Badir’s development and establishment of the SIRB network, an alliance of investors, technology entrepreneurs and innovation supporters in Saudi Arabia. Before joining Badir, Mr Al Sahhaf was a senior consultant for seven years with the Saudi Industrial Development Fund (SIDF) assisting companies in researching and implementing business opportunities in the construction, manufacturing and petrochemicals industrial sectors in local, regional and international markets. Mr Al Sahhaf has degrees in international marketing from the University of Strathclyde, Scotland and in marketing from King Fahd University of Petroleum and Minerals, Saudi Arabia.
Vice Governor of Small & Medium Enterprises Authority (SMEA)
Sami is the Vise Governor at Small and Medium Enterprises General Authority. In the past, he worked as a CIO in TVTC and consultant to mutable government and private companies in Technology and Digital Transformation.
Sami was the VP for Innovation and consultation ,and launched Bahr,a future work platform. He is a serial entrepreneur who founded and co-founded multiple startups, such as AL Mawred for e- publishing, Rwag to open Education, Junnah for Diabetes prevention and Kasb an ecommerce for home-based business. He always enjoys mentoring and startups and participating in committee to evaluate startups. Sami has bachelor degree in Computer Engineer, Master’s degree in Computer Science and post graduate research in Information Security.
Dr. Omar A. Almazroo is a Drug-VP consultant for the clinical trials in the Saudi Food & Drug Authority (SFDA). He led the process of establishing the pharmaceutical products evaluation directorate at SFDA, which is the scientific backbone of the drug sector since 2009. Dr. Almazroo was the first director appointed for pharmaceutical products evaluation. With his colleagues, he developed many of the current scientific practices in the directorate. He also initiated, coordinated and conducted two clinical studies at the University of Pittsburgh Medical Center (UPMC), one of which was Phase I/II – Investigational New Drug (IND) clinical study.
Dr. Almazroo graduated from School of Pharmacy, King Saud University with a Bachelor degree in Pharmaceutical Sciences. In 2009, he was among the top 10% of all graduates in the Master of Sciences in biopharmaceuticals from School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia. On 27 April 2013, he was one of the first Saudi pharmacists to complete the Certificate in Clinical and Translational Sciences (master degree level) from the School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. In 2017, he received his PhD in Pharmaceutical Sciences from University of Pittsburgh. The PhD research was focused on hepatic ischemia and reperfusion injury in liver transplantation. He conducted preclinical and clinical studies, while his research involved in using ex-vivo, in-vivo and simulation models for pharmacokinetics, developed several mass spectrometry assays and utilized PCR techniques for gene characterization.
Head, Innovation and Technology Transfer Management Office , KAIMRC
•PhD. College of Engineering, The University of Texas, USA (2011)
•MSc. College of Engineering , The University of Strathyclyde, Scotland, UK (2004)
•BSc. College of Engineering, King Fahad University of Petroleum and Minerals (KFUPM), Saudi Arabia (1999)
Director, Testing & Measurement Systems Dept., AlFaisaliah Group, Riyadh, Saudi Arabia (2012)
Postdoctoral Research Fellow, Biomedical Engineering Dept, University of Texas, San Antonio (2011 – 2012)
Supervisor, Engineering & Planning, Saudi Telecom Co. (STC) (2005 – 2009)
Manager Engineering of Special Networks (Biomedical), Saudi Telecom Co. (STC) (2003-2005)
Systems & Signals Engineer, Saudi Telecom Co. (STC) (1999-2005)
Skills and Interests
•Biomedical Image and Signal Processing
•Biomedical Pattern Recognition and Classification
•Biomedical Systems Modeling
2011 – 2015, Doctor of Philosophy (Ph.D.) – Bioethics/Medical Ethics, The University of Birmingham, College of Medical and Dental Sciences, UK. Thesis Title: Biomedical Ethics of Donating Blood for Molecular and Genetic Research in Saudi Arabia.
2008 – 2010, Master’s Degree, Bioethics, King Saud Bin Abdulaziz University for Health Sciences, School of Public Health, KSA: Thesis Title: Quality of Informed Consent for Invasive Procedures in Central Saudi Arabia.
2000 – 2006, Doctor of Philosophy (Ph.D.) – Biomedical Science, The University of Bradford, School of Medical Science, UK: , Thesis
Title: Characteristic of Haemophilus Influenza that Cause Eye Infections in Saudi Arabia.
1990-1995, Bachelors in Biochemistry, King Saud University, College of Science, KSA,
April 2016 up to date: Head-Bioethics Section/ Chairman-Institutional Review Board/ Associate Research Scientist, KAIMRC, KSA
July 2015 – April 2016: Associate Research Scientist, Biomedical Research Section, KAIMRC, KSA
March 2003 –Feb 2010: Senior Research Coordinator & IRB Officer, KAIMRC, KSA
July 1998 – March 2003: Acting Senior Clinical Research Coordinator, King Khaled Eye Specialist Hospital, KSA
Aug 1995 –July 1998: Forensic Laboratory Chemist, Forensic Evidence Department, Ministry of Interior, KSA
Skills & Interest
Co-Founder KAIMRC Project: I helped to manage and coordinated the KAIMRC project from the inception of the idea in 2003 to the inauguration in 2006. I served in the early stages of most of its projects like DNA banking, Cord blood banking, Education Section and the IRB. In addition to those activities I founded/co-founded the Clinical Research Section and The Biomedical Ethics Section a.k.a Bioethics Section.
Teaching: As faculty member, I supported many training and academic programs such as the Master of Bioethics, Courses in Research Methodology, Research philosophy, and Research designs. I also founded the Clinical Research Program in 2008 which is still active.
Research Mentoring: As an experienced researcher, I have used both qualitative as well as quantitative research designs with their differences in methodological and philosophical levels.
Research Coaching: I served as a research coach for many Saudi Clubs for Masters and Ph.D. students who face difficulties in managing and conducting their academic research through one-to-one coaching and group workshops.
Certified Trainer: I have two “Train The Trainers” certificates: the first is an international one in Clinical Research from Barnet International. The second is a national one as public dialog speaker in King Abdulaziz Center For National Dialogue.
Research Interest: Research Ethics, Islamic Bioethics, Informed Consent, IRB Regulations, Cross-culture Research, and Imperial Biomedical Ethics
Head Genetics Division, Department of Pediatrics , Associate Professor, King Saud bin Abdulaziz University for Health Sciences , MNG-HA
Dr. Majid Alfadhel is a Genetic and Pediatric Consultant at National Guard Health Affairs. Additionally, Dr. Alfadhel has been an associate professor at King Saud bin Abdulaziz University for the past five years. Alfadhel’s impressive educational background includes a Master’s degree in Epidemiology from the University of British Columbia, as well as fellowships in Neurometabolics and Biochemical Genetics.
Director and Senior Intellectual Property Counsel, Legal Affairs
Saudi Basic Industries Corporation (SABIC)
Zayd Alathari joined SABIC in February 2012 and is based in Riyadh. He is responsible for a team of attorneys and IP practitioners handling all aspects of intellectual property work for a number of Business Units, Manufacturing and Technology & Innovation teams in developing and implementing IP strategy, providing legal and IP counseling and contract support to enhance the value of SABIC technology. The team’s responsibilities include advising on, drafting and negotiating technology related agreements and patent portfolio management, patent preparation, prosecution and maintenance, freedom-to-practice, patent litigation and IP due diligence.
He has a Bachelor of Science from George Washington University, a Masters of Science from Johns Hopkins University and a Juris Doctor in Law from Washington College of Law, American University. He is admitted to practice before the United States Patent & Trademark Office, the Virginia Bar and the Washington, D.C. Bar, and prior to joining SABIC had over 18 years of law firm experience, including Venable LLP and Patton Boggs, LLP.
Prof. Mohamed S. Al Moamary, ABIM, FRCP(Edin), MBA-LS, FCCP
Executive Director, Medical Services, KAMC-Riyadh, Saudi Arabia Vice President, Development and Quality Management, KSAU-HS, Saudi Arabia Professor & Consultant, Pulmonary Medicine, KAMC-Riyadh Chairman, Saudi Initiative for Asthma Editor-in-Chief, Annals of Thoracic Medicine Riyadh, Saudi Arabia
Prof. Mohamed Al-Moamary is the Vice President, Development and Quality Management since
July 2013. He started his career in academia as the Director of Internal Medicine Residency
Training Program (2002-2004) in the Department of Medicine at King Abdulaziz Medical City-
Riyadh (KAMC-R). With the establishment of the college of Medicine at King Saud bin
Abdulaziz University for Health Sciences on 2004, he was a member of the commissioning
committee. He then appointed as the founding Associate Dean for Clinical Affairs where he led
the implementation of the curriculum at the KAMC-R and launched a faculty enhancement
program. He was the author of a unique Framework for Medical Interns’ Competencies. He also
led the innovative efforts to integrate patient Safety in the College of Medicine’s curriculum.
In the clinical field, Prof. Al-Moamary is practicing as a consultant in Pulmonary Medicine at
KAMC on 1997 till date. He is the founder of the first national pulmonary rehabilitation program
on 2000. His area of interest is airway diseases namely Asthma and COPD. He has Published
clinical research in respectable peer reviewed journals more than 40 papers in the area airway
diseases. He founded and chaired the Annual asthma meeting from 2001-2010. Prof. Al-
Moamary is a member of the Administrative Board of the Saudi Thoracic Society where he has
various contributions in the field of Pulmonary Medicine. He is the founder and Editor – in –
Chief of the Annals of Thoracic Medicine, a peer reviewed journal that was established on 2006.
He also the Chairman and primary author of the Saudi Initiative for Asthma (SINA), the national
guidelines for the diagnosis and management of asthma in adults and children. He organized and chaired the scientific committees of different meeting.
B.B.S.: College of Medicine, King Saud University, Riyadh, Saudi Arabia. (1989)
Arab Board in Internal Medicine (ABIM), (1994).
The Membership of the Royal Colleges of Physicians of the United Kingdom, MRCP (UK),
(1994). He was then elected as a fellow of the Royal College of Physician of Edinburgh,
Respiratory Medicine Fellowship, University of British Columbia, Canada (1996).
Consultant, Pulmonary Section, Department of Medicine, KAMC-Riyadh since 1997
Medical Director (Founder), Pulmonary Rehabilitation Center, KAMC-Riyadh since 1997
The National Order of Merit on the performance of duty – 1991
National Asthma committee Awards – 2—4
King Saud University Award for the Annals of Thoracic Medicine as ISI listed journal-January 2012
Member of the Board of Directors, Saudi Thoracic Society
Fellow, American Colleges of Chest Physicians (FCCP), USA
Fellow, Royal Colleges of Physicians of Edinburgh, UK
Head, Developmental Medicine Department (DMD), KAIMRC
Dr. Manal Alaamery is currently the Head of Developmental Medicine Department (DMD) and an active research scientist at King Abdullah International Medical Research Center (KAIMRC). She is an instructor at Harvard Medical School/ Children’s Hospital Boston.
During Dr. Manal Alaamery’s work and career, she received numerous awards and published in prestigious peer-reviewed scientific journals. She also taught several courses, led many initiatives and held several committee positions. Her long-term goal as a scientist is to use her extensive background and expertise in science to contribute to the medical field; develop programs, plans and strategies that could improve research and medicine in the Kingdom of Saudi Arabia and bridge the gap between research and clinical medicine by translating novel discoveries into clinical tests through cutting-edge techniques. She received her clinical and postgraduate training at the Laboratory of Molecular Medicine (LMM) at Harvard Medical School focusing on Hypertrophic and Dilated Cardiomyopathies, Neurological disorders, Muscular disorders, Hearing loss, Noonan spectrum, Connective tissue disorders, Pharmacogenetics and Cancer Genetics. She also holds a Doctoral (Ph.D.) degree in Molecular Genetics/Biology from Boston College and a Master of Science degree in Clinical Microbiology from Thomas Jefferson University. Two years ago at KAIMRC, she established the Developmental Medicine Department (DMD), which focuses on genetic disorders, therapy development and many other malformations such as neurological disorders and birth defects, and also hosts a satellite laboratory of KACST National project and is part of “The Saudi Genome Project”.
Dr. Majed Al Jeraisy is an experienced, dedicated and a determined leader. He has benchmarked programs and initiatives as the Chairman of the Research Office at King Abdullah International Medical Research Center. Research Office and is part of the bricks of success of this institution. He is also a promoter of knowledge and learning as an Assistant Professor in the College of Pharmacy at King Saud Bin Abdulaziz University for Health Sciences. Among his other professional expertise, he is also a Clinical Pharmacy Consultant at the Pediatric ICU of King Abdullah Children Specialty Hospital. With more than two decades of service, he is a person with outstanding integrity.
Dr. Jeraisy has authored and co-authored numerous and relevant scientific research projects in the field of Pediatrics, Pharmacotherapy, General Medicine, Biochemistry, Pharmacology and Toxicology that were published in reputable Journals. Some of his research projects were given outstanding recognitions in various Research Project competitions. He is actively working on current studies and clinical trials with the same goal of imparting his knowledge in the Medical and Scientific Community. In addition, he is also supervising research projects for the undergraduate students as well as post gradutes.
Chairman Intensive Care Department Medical Director Respiratory Services Assistant Professor King Saud Bin Abdulaziz University for Health Sciences
Dr. Yaseen Arabi – obtained his Internal Medicine Training at Wayne State University, Detroit, MI, USA (1992-1994), then he was the Chief Medical Resident at the same institution (1994-1995).
He obtained pulmonary and critical care fellowship training at the University of Wisconsin, Madison, WI, USA (1995-1998). In 1998, he joined King Abdulaziz Medical City, Riyadh, Saudi Arabia. He is currently the Chairman of the Intensive Care Department and the Medical Director, Respiratory Services. He is also the member of several institutional committees including being the Deputy Chairman of Research Committee as well as a member of several international committees for the Society of Critical Care Medicine (SCCM) and the American College of Chest Physician (ACCP). He is also a member of the Executive Board of the Saudi Critical Care Society. He received multiple grants and awards and has been an investigator on several multicenter international trials including the Lung Open Ventilation Study (LOVS), The Use of Non-Invasive Ventilation in Post Extubation Failure, the PROphylaxis of ThromboEmbolism in Critical Care Trial (PROTECT), OSCILLation for ARDS Treated Early (OSCILLATE ) among others. He has more than 80 publications including articles in the New England Journal of Medicine (NEJM), JAMA, Lancet, and Critical Care Medicine. He received international awards & grants for King Abdullah International Medical Research Center Senior Research Award (2010), Al-Ghad & Colleagues Medical Innovation Award, Saudi Arabia (2010) and Bary A. Shapiro Memorial Award for Excellence in Critical Care Management, USA (2010). Dr. Arabi is Chairman, Intensive Care Department, Medical Director, Respiratory Services, Assistant Professor, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City Riyadh, Kingdom of Saudi Arabia
Chairman, Population Health Research Section & National Biobanking, KAIMRC
Dr. Ada Alqunaibet is currently the Chairman of Population Health Research Section and National Biobanking in KAIMRC.
Dr. Al Qunaibet graduated with Bachelor of Medicine and Surgery (MBBS) from King Saud University in 2 0 0 2 with a Masters in Medical Education from King Saud bin Abdulaziz University for Health Sciences (KSAU-HS) in 2008. She obtained her PhD in Epidemiology from the University of North Carolina at Chapel Hill, USA in 2016. In addition, Dr. Al Qunaibet has several peer reviewed publications in international journals and has been an active member of several scientific committees.
Director General, General Directorate for Research Grants.
King Abdulaziz City for Science and Technology (KACST).
He received his M.Sc. and Ph.D. degrees in resource economics from Oklahoma State University – college of agriculture and natural resources – USA in year 1996 .
During his professional career, Dr Alabdulkader has represented KACST officially in diverse occasions at national, regional and international levels among which a member of Saudi Arabia official delegation at the United Nation Convention for Climate Change and Kyoto Protocol (UNFCC & KP), and Asian lead negotiator on the green climate change fund.
The scientific record of Dr. Alabdulkader has shown that he has about 60 scientific production including research projects, journal and conference papers, patents, and books in his scientific discipline and professional career including economic modeling, economic efficiency, economics of climate change, economic and technical feasibility studies and others.
Also, he serviced as a consultant and an advisory board member for some international organizations and scientific international associations.
Associate Professor Department of Maxillofacial surgery and diagnostic sciences College of Dentistry King Saud University
* (Abstract) “CENTRAL GIANT CELL GRANULOMA OF THE JAWS AND GIANT CELL TUMOR OF LONG BONES. A CLINICOPATHOLOGIC, CYTOMETRIC, AND IMMUNOHISTOCHEMICAL COMPARATIVE STUDY”, M. AlSheddi, H. Mosadomi, F. Al Dayel
Presented at the 58th Annual Meeting and Continuing Education Program of the American Academy of Oral and Maxillofacial Pathology and was accepted for publication.
*(Poster) “EFFECTS OF FLUORIDE ON AMELOGENIN AND MMP-20 EXPRESSION IN AMELOBLASTS”, M.A. ALSHEDDI, E. PRAVDA, J. DOBECK, and Z. SKOBE
Presented at the ADEA/AADR/CADR Meeting (2006)
American Board of Oral and Maxilofacial Pathology
2006 Doctorate of Medical Sciences
Harvard School of Dental Medicine
American Academy of Oral and Maxillofacial Pathology
2000 Master of Science
College of Dentistry
King Saud University
1995 Bachelor of Science in Dental Surgery
College of Dentistry
King Saud University
2007 Assistant Professor
College of Dentistry
King Saud University
College of Dentistry
King Saud University
College of Dentistry
King Saud University
Business development at Badir for Biotechnology incubator
Badir biotechnology Incubator.
Ms.Maha Abuyabis is a business development advisor at Badir Technology Incubator (the Biotechnology sector), She received her BSc. Biotechnology from Bangalore University, India and currently pursuing her master in finance from DCU university. Ms. Maha worked as a lab technologist after graduating and worked mainly in Biotechnology research and deviated her career to business development . She worked with around 25 start up and 3 patents from product development till they launched to the market.She played role in assessing the projects and looked into business viability and the technology readiness.
She is passionate in technology commercialization and building an ecosystem that links investors with technology entrepreneurs.
Dr. Aljohani is originally from Saudi Arabia he received his bachelor degree from King Saud University in Riyadh in year 2000, his Master degree in Clinical Drug Development from Queen Mary University of London, School of Medicine and Dentistry in 2009, and his PhD in Clinical Pharmacology, Drug Bioequivalence from QMUL, School of Medicine and Dentistry, UK in year 2015.
Dr. Aljohani clinical and research skills and interests include the following: Clinical pharmacology, clinical trials, pharmaceutical bioequivalence, internal medicine. Therapeutics and therapeutic drug monitoring. Pharmaceutical analysis and laboratory skills, including working on mass spectrometric (MS), liquid chromatographic (LC) and capillary electrophoresis (CE), fluorescence, UV-Vis spectrophotometry according to GLP guidelines. Advanced expertise in dissolution testing
President, Saudi Association for Public Health.Chairman, Community & Environmental Health, College of Public Health and Health Informatics .Associate Professor, College of Medicine, King Saud bin Abdulaziz University for Health Sciences .National Guard Health Affairs, KAMC-RD
President, Saudi Association for Public Health
Chairman, Community & Environmental Health, College of Public Health and Health Informatics
Associate Professor, College of Medicine, King Saud bin Abdulaziz University for Health Sciences
National Guard Health Affairs, KAMC-RD
More than 20 years experience in leading positions in medicine and health care, primary care, public health, medical education and healthcare management. Such positions include Consultant Family and Community Medicine since 1992; Founding Executive Director of PHC (Kingdom-wide) National Guard Health Affairs Saudi Arabia; Founding Director of National Guard Comprehensive Clinic; Chairman, Family & Community Medicine, King Abdulaziz Medical City (KAMC); Founding Director of Accreditation Recognition and Committee of the Saudi Board in Family and Community Medicine; Founding Member of the Saudi Board in Family & Community Medicine, Founding Faculty Member, College of Medicine, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS); Founding Chair, Public Health, KSAU-HS; Chair, Community & Environmental Health, KSAU-HS; Postgraduate Tutor, Department of General Practice, University of Liverpool, cited in Who’s Who among outstanding health professionals. Associate of American college of Healthcare Executives.
Published more than 43 publications in peer-review journals nationally and internationally; a chapter on quality in medical education in international book; Winner of the European Prize in Research in General Practice (SIMG-JFR, 1991); Distinguished Member of Faculty of Public Health (UK)2012, Served as member, editorial board of SMJ & BJGP; Received many appreciation letters and certificates. Also served the Community in a number of leading positions and projects. This includes Deputy President of Imam Mohamed bin Saud Charity Organization, Founding Member of Society of Community education and Rehabilitation. Elected President, Saudi Association for Public Health (SAPH).
Klaus Lindpaintner, MD, MPH, FACP serves as VP and Global Head, Human Genetics and Computational Biomedicine, at Pfizer, Inc. where he is in charge of deploying genetic approaches to drug target discovery and validation and to precision medicine concept across therapeutic areas. Previously, he held senior positions at Hoffman-La Roche, where he spearheaded the company’s efforts in personalized health care and was responsible for the respective ac-tivities in translational research that have rebranded the company’s image; at Thermo Fisher Scientific,, where he served as Chief Scientific Officer; at SDIX, a specialty-antibody-focused biotechnology company; and on the faculty of Harvard Medical School. Klaus has co-authored some 250 scientific papers, and holds honorary and adjunct professorships at several academic institu-tions. He serves on numerous boards, working groups, and advisory panels for trade organizations, regu-latory authorities, and non-governmental organizations on issues related to the successful implementa-tion and leverage of novel technologies in health care and industrial applications, as well as on the ethical and societal impact of these technologies. Klaus graduated from Innsbruck University Medical School with a degree in medicine, and from Harvard University with a degree in public health. He pursued post-grad-uate training and specialization in internal medicine, cardiology, and clinical and molecular genetics in the US and Germany, and is a Diplomate of the Boards in these specialties.
Supervisor of Technology Transfer Intellectual Property
Eng. Ahmed Aldraihem has a master degree of Science in Engineering and Technology Management, Portland State University, USA. He finished his bachelor degree at Biomedical Technology at King Saud University. Currently, Engr. Ahmed Aldraihem works as Supervisor Technology Transfer Intellectual Property of ITTMO at KAIMRC. Aside of his current role at ITTMO, he managed several projects at KAIMRC such as screening Intellectual Property for over 300 publications and articles generated by KCIAMRC’s researchers and scientists, commissioning equipment at KAIRMC-ER, and building up ITTMO manual. He used to work as a Consultant at Performance Solutions at GE Healthcare. Prior to that, he worked as Field Service Engineer at General Electric Healthcare. He has successful participated at Publication titled “Site selection for an engineering and management services firm in Saudi Arabia.”